Cargando…

Extended Use of The Spanner® Temporary Prostatic Stent in Catheter-Dependent Men with Comorbidities

PURPOSE: This US FDA investigational device exemption (IDE) study evaluated the extended use of The Spanner® Temporary Prostatic Stent in catheter-dependent men with urinary retention who were not deemed candidates for corrective surgery but demonstrated bladder contractility. MATERIALS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Cambio, Angelo J., Roach, Richard M., Arnold, Paul, Cambio, Joseph, Gluck, Clifford D., Heron, Sean P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831058/
https://www.ncbi.nlm.nih.gov/pubmed/35154313
http://dx.doi.org/10.1155/2022/7367851
_version_ 1784648417526415360
author Cambio, Angelo J.
Roach, Richard M.
Arnold, Paul
Cambio, Joseph
Gluck, Clifford D.
Heron, Sean P.
author_facet Cambio, Angelo J.
Roach, Richard M.
Arnold, Paul
Cambio, Joseph
Gluck, Clifford D.
Heron, Sean P.
author_sort Cambio, Angelo J.
collection PubMed
description PURPOSE: This US FDA investigational device exemption (IDE) study evaluated the extended use of The Spanner® Temporary Prostatic Stent in catheter-dependent men with urinary retention who were not deemed candidates for corrective surgery but demonstrated bladder contractility. MATERIALS AND METHODS: The Spanner was placed for 3 cycles of 30 days in catheter-dependent men with comorbid conditions, confirmed detrusor contractility, and catheter-associated discomfort. At each visit, postvoid residual, maximum flow rate, international prostate symptom score, quality of life, and adverse events were assessed. Voiding success was defined as PVR ≤ 150 ml at all visits. RESULTS: One hundred seven men were enrolled at 8 US sites; 82/107 (76.6%) completed the trial, and 79/107 (73.8%) successfully maintained PVR ≤ 150 ml for the trial duration. Patients were 77.1 ± 10.6 years old; 63/107 (58.9%) were dependent on Foley and 40/107 (37.4%) on intermittent catheterization for 36.0 ± 39.3 days and 30.2 ± 45.8 days, respectively. 25/107 (23.4%) discontinuations were primarily due to voluntary patient withdrawal 9/107 (8.4%), investigator-initiated withdrawal 8/107 (7.5%), or lack of effectiveness 4/107 (3.7%). During Spanner use, the mean Q(max) was 11.2 ± 6.6, mean IPSS was 7.5 ± 6.4, and mean QOL was 2.0 ± 1.6. The most prevalent device-related adverse events were asymptomatic bacteriuria 25/107 (23.4%), discomfort 10/107 (9.4%), and urinary urgency 8/107 (7.5%). No device-related serious AEs were reported. CONCLUSIONS: This study demonstrates that catheter-dependent men with sufficient bladder contractility can achieve volitional voiding and successful bladder drainage using The Spanner Temporary Prostatic Stent for extended periods of time.
format Online
Article
Text
id pubmed-8831058
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-88310582022-02-11 Extended Use of The Spanner® Temporary Prostatic Stent in Catheter-Dependent Men with Comorbidities Cambio, Angelo J. Roach, Richard M. Arnold, Paul Cambio, Joseph Gluck, Clifford D. Heron, Sean P. Adv Urol Research Article PURPOSE: This US FDA investigational device exemption (IDE) study evaluated the extended use of The Spanner® Temporary Prostatic Stent in catheter-dependent men with urinary retention who were not deemed candidates for corrective surgery but demonstrated bladder contractility. MATERIALS AND METHODS: The Spanner was placed for 3 cycles of 30 days in catheter-dependent men with comorbid conditions, confirmed detrusor contractility, and catheter-associated discomfort. At each visit, postvoid residual, maximum flow rate, international prostate symptom score, quality of life, and adverse events were assessed. Voiding success was defined as PVR ≤ 150 ml at all visits. RESULTS: One hundred seven men were enrolled at 8 US sites; 82/107 (76.6%) completed the trial, and 79/107 (73.8%) successfully maintained PVR ≤ 150 ml for the trial duration. Patients were 77.1 ± 10.6 years old; 63/107 (58.9%) were dependent on Foley and 40/107 (37.4%) on intermittent catheterization for 36.0 ± 39.3 days and 30.2 ± 45.8 days, respectively. 25/107 (23.4%) discontinuations were primarily due to voluntary patient withdrawal 9/107 (8.4%), investigator-initiated withdrawal 8/107 (7.5%), or lack of effectiveness 4/107 (3.7%). During Spanner use, the mean Q(max) was 11.2 ± 6.6, mean IPSS was 7.5 ± 6.4, and mean QOL was 2.0 ± 1.6. The most prevalent device-related adverse events were asymptomatic bacteriuria 25/107 (23.4%), discomfort 10/107 (9.4%), and urinary urgency 8/107 (7.5%). No device-related serious AEs were reported. CONCLUSIONS: This study demonstrates that catheter-dependent men with sufficient bladder contractility can achieve volitional voiding and successful bladder drainage using The Spanner Temporary Prostatic Stent for extended periods of time. Hindawi 2022-02-03 /pmc/articles/PMC8831058/ /pubmed/35154313 http://dx.doi.org/10.1155/2022/7367851 Text en Copyright © 2022 Angelo J. Cambio et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Cambio, Angelo J.
Roach, Richard M.
Arnold, Paul
Cambio, Joseph
Gluck, Clifford D.
Heron, Sean P.
Extended Use of The Spanner® Temporary Prostatic Stent in Catheter-Dependent Men with Comorbidities
title Extended Use of The Spanner® Temporary Prostatic Stent in Catheter-Dependent Men with Comorbidities
title_full Extended Use of The Spanner® Temporary Prostatic Stent in Catheter-Dependent Men with Comorbidities
title_fullStr Extended Use of The Spanner® Temporary Prostatic Stent in Catheter-Dependent Men with Comorbidities
title_full_unstemmed Extended Use of The Spanner® Temporary Prostatic Stent in Catheter-Dependent Men with Comorbidities
title_short Extended Use of The Spanner® Temporary Prostatic Stent in Catheter-Dependent Men with Comorbidities
title_sort extended use of the spanner® temporary prostatic stent in catheter-dependent men with comorbidities
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831058/
https://www.ncbi.nlm.nih.gov/pubmed/35154313
http://dx.doi.org/10.1155/2022/7367851
work_keys_str_mv AT cambioangeloj extendeduseofthespannertemporaryprostaticstentincatheterdependentmenwithcomorbidities
AT roachrichardm extendeduseofthespannertemporaryprostaticstentincatheterdependentmenwithcomorbidities
AT arnoldpaul extendeduseofthespannertemporaryprostaticstentincatheterdependentmenwithcomorbidities
AT cambiojoseph extendeduseofthespannertemporaryprostaticstentincatheterdependentmenwithcomorbidities
AT gluckcliffordd extendeduseofthespannertemporaryprostaticstentincatheterdependentmenwithcomorbidities
AT heronseanp extendeduseofthespannertemporaryprostaticstentincatheterdependentmenwithcomorbidities